Related Experiment Video

Updated: Mar 15, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.6K

7th Japan Bioanalysis Forum symposium: regulated bioanalysis, to a new stage

Takahiro Nakamura1

  • 1Shin Nippon Biomedical Laboratories Ltd., 2438, Miyanoura, Kagoshima, 891-1394, Japan.

Bioanalysis
|September 15, 2016
PubMed

Keywords:
ADCDGJBFbioanalysisbiomarkerguidanceguidelinesymposium

More Related Videos

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring17:16

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring

Published on: December 9, 2010

11.0K
Updated Protocol for the Assembly and Use of the Minibioreactor Array (MBRA)09:38

Updated Protocol for the Assembly and Use of the Minibioreactor Array (MBRA)

Published on: September 5, 2025

1.0K

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
199
Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
506